Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs

Biochimica et Biophysica Acta - General Subjects

Volumn 1619, Issue 2, 2003, Pages 177-186

  Buss, Joan L ^a   Ponka, Prem ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Condensation; Hydrolysis; Iron chelator; Iron mobilization; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE BENZOYLHYDRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; ALDEHYDE; AMINO ACID; BUFFER; CHELATING AGENT; HYDRAZIDE; HYDRAZONE DERIVATIVE; IRON; IRON 59; PHOSPHATE; PYRIDOXAL 2 CHLOROBENZOYLHYDRAZONE; PYRIDOXAL 3 CHLOROBENZOYLHYDRAZONE; PYRIDOXAL 4 CHLOROBENZOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; PYRODIXAL BENZOYLHYDRAZONE; SALICYLALDEHYDE BENZOYLHYDRAZONE; SALICYLALDEHYDE ISONICOTINOYLHYDRAZONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CATALYSIS; CELL CULTURE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG HYDROLYSIS; HUMAN; HUMAN CELL; IRON KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; TOXICITY;

ANIMALS; CATIONS; CELL SURVIVAL; CELLS, CULTURED; DRUG DESIGN; HALF-LIFE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INHIBITORY CONCENTRATION 50; IRON; IRON CHELATING AGENTS; ISONIAZID; MICE; MOLECULAR STRUCTURE; PYRIDOXAL; RETICULOCYTES; TIME FACTORS;

EID: 0037454748     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(02)00478-6     Document Type: Article

References (31)

1. Porter J.B. Practical management of iron overload. Br. J. Haematol. 115:2001;239-252.
2. Hershko C., Konijn A.M., Link G. Iron chelators for thalassaemia. Br. J. Haematol. 101:1998;399-406.
3. Kontoghiorghes G.J., Aldouri M.A., Hoffbrand A.V., Barr J., Wonke B., Kourouclaris T., Sheppard L. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br. Med. J. 295:1987;1509-1512.
4. Olivieri N.F., Koren G., St Louis P., Freedman M.H., McClelland R.A., Templeton D.M. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin. Hematol. 27:1990;101-104.
5. Berdoukas V., Bentley P., Frost H., Schnebli H.P. Toxicity of oral iron chelator L1. Lancet. 341:1993;1088.
6. Cikrt M., Ponka P., Necas E., Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol. 45:1980;275-283.
7. Ponka P., Borova J., Neuwirt J., Fuchs O., Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta. 586:1979;278-297.
8. Ponka P., Borova J., Neuwirt J., Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97:1979;317-321.
9. Ponka P., Richardson D., Baker E., Schulman H.M., Edward J.T. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biophys. Acta. 967:1988;122-129.
10. Baker E., Richardson D., Gross S., Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 15:1992;492-501.
11. Edward J.T., Ponka P., Richardson D.R. Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy. BioMetals. 8:1995;209-217.
12. Edward J.T., Chubb F.L., Sangster J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients. Can. J. Physiol. Pharm. 75:1997;1362-1368.
13. Buss J.L., Arduini E., Ponka P. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the Fe-chelator complexes. Biochem. Pharmacol. 64:2002;1689-1701.
14. Blaha K., Cikrt M., Nerudova J., Fornuskova H., Ponka P. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood. 91:1998;4368-4372.
15. Richardson D.R., Vitolo L.W., Baker E., Webb J. Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral, and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol. Met. 2:1989;69-76.
16. Lees-Gayed N.J., Abou-Taleb M.A., El-Bitash I.A., Iskander M.F. Studies on biologically active acylhydrazones: Part 1. Acid-base equilibria and acid hydrolysis of pyridoxal aroylhydrazones and related compounds. J. Chem. Soc., Perkin Trans. 2:1992;213-217.
17. Edward J.T., Gauthier M., Chubb F.L., Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Eng. Data. 33:1988;538-540.
18. Morgan E.H. Chelator-mediated iron efflux from reticulocytes. Biochim. Biophys. Acta. 733:1983;39-50.
19. 59Fe. Biochim. Biophys. Acta. 757:1983;306-315.
20. Matsushima Y., Martell A.E. Electron absorption spectra and molecular species in methanol solution. J. Am. Chem. Soc. 89:1967;1322-1330.
21. Metzler D.E. Equilibria between pyridoxal and amino acids and their imines. J. Am. Chem. Soc. 79:1957;485-490.
22. Richardson D.R., Tran E.H., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 86:1995;4295-4306.
23. Buss J.L., Arduini E., Shephard K.C., Ponka P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines efflux of Fe complexes and toxicity in K562 cells. Biochem. Pharmacol. 2001;. (submitted for publication).
24. Murphy T.B., Rose N.J., Schomaker V., Aruffo A. Syntheses of iron(III) aroyl hydrazones containing pyridoxal and salicylaldehyde. The crystal and molecular structure of two iron(III)-pyridoxal isonicotinoyl hydrazone complexes. Inorg. Chim. Acta. 108:1985;183-194.
25. Sarel S., Cohen S., Avramovici-Grisaru S. Iron chelators of the class of pyridoxal acylhydrazone: Part 5. Crystal structure and patterns of hydrogen bonding in pyridoxal isonicotinoyl hydrazone (PIH). Heterocycles. 47:1998;1033-1042.
26. Avramovici-Grisaru S., Sarel S., Cohen S., Bauminger R.E. The synthesis, crystal and molecular structure, and oxidation state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulphate. Isr. J. Chem. 25:1985;288-292.
27. Vitolo M.L., Hefter G.T., Clare B.W., Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class: Part II. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta. 170:1990;171-176.
28. Richardson D.R., Vitolo M.L., Hefter G.T., May P.M., Clare B.W., Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class: Part 1. Ionization characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta. 170:1990;165-170.
29. Martell A.E., Smith R.M. Critical Stability Constants. vol. 3:1977;Plenum, New York.
30. Tsafack A., Loyevsky M., Ponka P., Cabantchik Z.I. Mode of action of iron (III) chelators as antimalarials: IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J. Lab. Clin. Med. 127:1996;574-582.
31. Buss J.L., Neuzil J., Gellert N., Weber C., Ponka P. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron chelating properties. Biochem. Pharmacol. 2002;. (in press).